Riskpilot← Back to searchSign inGet full accessAlligator Bioscience AB
ABActiveOrg 5565978201Scheelevägen 2Research and experimental development on natural sciences and engineering · NACE 7210Est. 200010-19 employees
Revenue 2024
SEK 57,8M
0% vs 2023
EBITDA margin
-405.2%
+6% vs 2023
Equity ratio
-120.2%
Financial strength
Net profit 2024
SEK -231M
+7% vs 2023
| Revenue | SEK 57,8M | +0% |
| EBITDA | SEK -234,1M | +6% |
| Net profit | SEK -231M | +7% |
| Total assets | SEK 104,6M | +0% |
| Equity | SEK -125,7M | -998% |
| Employees | — | — |
Legal name
Alligator Bioscience AB
Org number
5565978201
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
21 september 2000
Share capital
SEK 607 000
Employees
10-19
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna eller en av dem i förening med Frederiksen, Søren Bregenholt Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget skall direkt eller genom dotterbolag eller andra intressebolag, bedriva forsknings- och utvecklingsarbete samt tillverkning och handel inom proteinkemiområdet jämte med detta förenlig verksamhet.
Address
Scheelevägen 2
Email
info@alligatorbioscience.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | 26 959 | 4 358 | 4 352 | 12 943 | 36 000 | 58 000 | 57 767 |
| Staff expenses | — | — | — | — | — | — | — | — | — | — |
| EBITDA | 215 675 | −32 307 | −60 250 | −147 178 | −209 256 | −138 872 | −136 718 | −189 000 | −248 000 | −234 064 |
| Depreciation & amort. | −12 667 | −2 555 | −3 204 | −5 902 | −5 812 | −5 658 | −5 084 | −4 000 | −1 000 | −961 |
| EBIT | 203 008 | −34 862 | −63 454 | −153 080 | −215 068 | −144 530 | −141 802 | −193 000 | −249 000 | −235 025 |
| Net financials | 4 370 | −14 393 | −2 281 | −2 549 | 3 618 | 14 823 | 35 | — | 1 000 | 2 925 |
| Profit before tax | 207 379 | −49 256 | −65 736 | −150 043 | −210 963 | −129 270 | −141 765 | −193 000 | −248 000 | −231 002 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| Net profit | 207 379 | −49 256 | −65 736 | −150 043 | −210 963 | −129 270 | −141 765 | −193 000 | −248 000 | −231 002 |
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 417 857 | 701 608 | 641 883 | 508 156 | 282 219 | 142 038 | 326 488 | 148 000 | 105 000 | 104 568 |
| Equity | 398 570 | 677 013 | 616 806 | 468 309 | 246 643 | 117 416 | 284 424 | 91 000 | 14 000 | −125 697 |
| Long-term debt | 0 | 0 | 0 | 0 | 426 | 432 | 143 | 0 | 0 | 0 |
| Short-term debt | 19 287 | 24 595 | 25 078 | 39 847 | 35 150 | 24 190 | 41 921 | 57 000 | 91 000 | 191 586 |
| Total debt | 19 287 | 24 595 | 25 078 | 39 847 | 35 576 | 24 622 | 42 064 | 57 000 | 91 000 | 191 586 |
EBITDA margin
-405.2%
This company
15.8%
Market median
-2665% vs market
20152024
Equity ratio
-120.2%
This company
38.2%
Market median
-415% vs market
20152024
Return on equity
-23100200000.0%
This company
18.4%
Market median
-125544565317% vs market
20152024
Net profit margin
-399.9%
This company
8.1%
Market median
-5037% vs market
20152024
Asset turnover
0.55×
This company
1.12×
Market median
-51% vs market
20152024
Debt / equity
1.83×
This company
0.62×
Market median
-195% vs market
20152024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Bolagsverket / SCB · Period 2015-01-01 – 2015-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
LJ Chief Auditor | Chief Auditor | 2023 | — | — |
OC Chief Auditor | Chief Auditor | 2020 | — | — |
SB Chief Executive Officer | Chief Executive Officer | 2021 | — | — |
PG Chief Executive Officer | Chief Executive Officer | 2020 | — | — |
AO Chief Auditor | Chief Auditor | 2022 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Deputy Board Member | 2023 | — | — | |
| Board of Directors | 2023 | — | — | |
| Chairman | 2022 | — | — | |
| Deputy Board Member | 2020 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2023 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2024 | — | — | |
| Chairman | 2025 | — | — | |
| Chairman | 2020 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2020 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Alligator Bioscience AB 
A Bioscience Incentive ABBoard members of Alligator Bioscience AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Lars Johan Peter Gunnarsson | Chief Auditor | 0 companies |
| Ola Christopher Carelius Larsmon | Chief Auditor | 0 companies |
| Søren Bregenholt Frederiksen | Chief Executive Officer | 0 companies |
| Per Göran Oskar Norlén | Chief Executive Officer | 0 companies |
| Anders Ola Bjärehäll | Chief Auditor | 0 companies |
| Åsa Anette Sundstedt | Deputy Board Member | 0 companies |
| Laura Ila von Schantz | Board of Directors | 0 companies |
| Anders Olof Adolf Ekblom | Chairman | 0 companies |
| Kirsten Aarup Drejer | Deputy Board Member | 0 companies |
| Graham Keith Dixon | Board of Directors | 0 companies |
| Denise Elaine Goode | Board of Directors | 0 companies |
| Tova Viveka Ulrika Landström | Board of Directors | 0 companies |
| Staffan Erik Encrantz | Board of Directors | 0 companies |
| Anna Ulrika Danielsson | Board of Directors | 0 companies |
| Karin Louise Nordbladh | Board of Directors | 0 companies |
| Hans-Peter Albert Ostler | Chairman | 0 companies |
| Peter James Arthur Benson | Chairman | 0 companies |
| Karl Arne Krister Borrebaeck | Board of Directors | 0 companies |
| Kenth Ingemar Petersson | Board of Directors | 0 companies |
| Veronica Wallin | Board of Directors | 0 companies |
| Lennart Erik Jonas Sjögren | Board of Directors | 0 companies |
| Eva Ulrika Saers | Board of Directors | 0 companies |